CROSSJECT SA
CROSSJECT SA is a federal contractor, registered under UEI NLXZHCL3NLL3 and CAGE code FBEF0. It has been awarded $104,152,984 across 1 federal contract. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include Department Of Health And Human Services.
Contact Information
Registration and classification details
Registration
UEI Code
NLXZHCL3NLL3CAGE Code
FBEF0Entity Structure
Corporate Entity (Not Tax Exempt)Established
N/ABusiness Classifications
NAICS Codes
Federal Contracting Overview
Award totals, agency breakdown, NAICS distribution, and geographic footprint.
AI Capability Profile
CROSSJECT SA specializes in the advanced research, development, and delivery of biotechnological medical countermeasures, with a focused expertise in autoinjector systems for acute neurological emergencies. Their technical capabilities center on the design, formulation, and regulatory pathways for a...
CROSSJECT SA specializes in the advanced research, development, and delivery of biotechnological medical countermeasures, with a focused expertise in autoinjector systems for acute neurological emergencies. Their technical capabilities center on the design, formulation, and regulatory pathways for adult and pediatric midazolam autoinjectors, particularly those seeking or holding Emergency Use Authorization or full FDA approval for the treatment of status epilepticus. The contractor demonstrates proficiency in translational biopharmaceutical development, including drug delivery system engineering, stability testing, and compliance with cGMP and FDA regulatory standards for injectable therapeutics. Their specialization in rapid-response biotech solutions positions them as a niche provider in emergency seizure management technologies, bridging preclinical innovation with clinical deployment. CROSSJECT SA has delivered services to the Department of Health and Human Services, primarily supporting public health preparedness initiatives through the development of FDA-authorized medical devices. Their engagement reflects a targeted partnership focused on accelerating the availability of life-saving therapeutics during public health emergencies, suggesting alignment with HHS agencies such as BARDA or CDC in emergency medical countermeasure programs. The contractor’s primary industry focus is in biotechnology research and development, specifically non-nanotech applications in neuropharmacology and autoinjector delivery systems. This vertical specialization places them at the intersection of pharmaceutical innovation and emergency medical device manufacturing, serving a critical gap in pediatric and adult seizure care infrastructure. CROSSJECT SA operates as a small business entity (2L structure) headquartered in Dijon, France, with no publicly disclosed federal certifications. Their geographic presence is international, yet their government market positioning is narrowly defined by a single, highly specialized contract with a U.S. federal health agency, indicating a focused, mission-driven approach to supporting U.S. public health security through advanced biotech solutions.
Key Performance Metrics
Awards Count
All time
Active
Currently performing
Completed
Past period of performance
Total Awards
All time
Contracts
Prime · all time
Subcontracts
Sub · all time
Grants
Prime · all time
Subgrants
Sub · all time
